• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

COUMARIN Drug Record

  • Summary
  • Interactions
  • Claims
  • COUMARIN chembl:CHEMBL6466 Approved

    Alternate Names:

    LODEMA
    COUMARIN
    NSC-8774

    Drug Info:

    (0 More Sources)

    Publications:

    Oscarson M et al., 1998, Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase., FEBS Lett
    Hadidi H et al., 1997, A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin., Food Chem Toxicol
    Gao N et al., 2016, Gene polymorphisms and contents of cytochrome P450s have only limited effects on metabolic activities in human liver microsomes., Eur J Pharm Sci
    Wang H et al., 2011, Association analysis of CYP2A6 genotypes and haplotypes with 5-fluorouracil formation from tegafur in human liver microsomes., Pharmacogenomics
    Li L et al., 2006, New cytochrome P450 2D6*56 allele identified by genotype/phenotype analysis of cryopreserved human hepatocytes., Drug Metab Dispos
    Haberl M et al., 2005, Three haplotypes associated with CYP2A6 phenotypes in Caucasians., Pharmacogenet Genomics
    Fukami T et al., 2005, Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity., Drug Metab Dispos
    Kiyotani K et al., 2003, Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9)., Pharmacogenetics
    Yoshida R et al., 2003, Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro., Clin Pharmacol Ther
    Xu C et al., 2002, An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles., Biochem Biophys Res Commun
    Pitarque M et al., 2001, Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity., Biochem Biophys Res Commun
    Kitagawa K et al., 2001, CYP2A6*6, a novel polymorphism in cytochrome p450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity., J Biol Chem
    Meunier V et al., 2000, Expression and induction of CYP1A1/1A2, CYP2A6 and CYP3A4 in primary cultures of human hepatocytes: a 10-year follow-up., Xenobiotica
    Oscarson M et al., 1999, Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism., FEBS Lett
    Yamano S et al., 1990, The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes., Biochemistry
    Fukami T et al., 2005, A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity., Biochem Pharmacol
    Oscarson M et al., 2002, Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity., Hum Mutat
    Donato MT et al., 2000, CYP2A5/CYP2A6 expression in mouse and human hepatocytes treated with various in vivo inducers., Drug Metab Dispos
    Kumondai M et al., 2018, Functional characterization of 9 CYP2A13 allelic variants by assessment of nicotine C-oxidation and coumarin 7-hydroxylation., Drug Metab Pharmacokinet
    Neuhaus et al., 2001, [An uncommon cause of severe soft tissue bleeding during phenprocoumon treatment]., Dtsch. Med. Wochenschr.
    Lipps et al., 1996, Cathepsin B of Schistosoma mansoni. Purification and activation of the recombinant proenzyme secreted by Saccharomyces cerevisiae., J. Biol. Chem.
    Silverstein et al., 1985, Activation of immobilized plasminogen by tissue activator. Multimolecular complex formation., J. Biol. Chem.
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Kudo et al., 1998, Evidence for modulation of osteocalcin containing gamma-carboxyglutamic acid residues synthesis by insulin-like growth factor-I and vitamin K2 in human osteosarcoma cell line MG-63., Eur. J. Endocrinol.
  • COUMARIN   CYP2A13

    Interaction Score: 5.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29342418


    Sources:
    PharmGKB

  • COUMARIN   CYP2A6

    Interaction Score: 4.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9827545 9409631 27339126 21521021 16679388 16041240 15900015 14583682 12844137 11779172 11394901 11278503 10923861 10544257 2322567 15993850 12325023 11038160


    Sources:
    PharmGKB

  • COUMARIN   CTSB

    Interaction Score: 3.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8576174


    Sources:
    NCI

  • COUMARIN   F9

    Interaction Score: 1.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11455667


    Sources:
    NCI

  • COUMARIN   BGLAP

    Interaction Score: 0.45

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9578515


    Sources:
    NCI

  • COUMARIN   PLG

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    3160707


    Sources:
    NCI

  • COUMARIN   CYP2C9

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • COUMARIN   CYP2C19

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • COUMARIN   CYP1A2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • COUMARIN   CYP2D6

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • COUMARIN   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • COUMARIN   NFE2L2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DTC: COUMARIN

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL6466 ChEMBL Drug ID

    Drug Info:

    Publications:
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

  • NCI: COUMARIN

    • Version: 14-September-2017

    Alternate Names:
    C397 NCI drug code

    Drug Info:

    Publications:
    Silverstein et al., 1985, Activation of immobilized plasminogen by tissue activator. Multimolecular complex formation., J. Biol. Chem.
    Kudo et al., 1998, Evidence for modulation of osteocalcin containing gamma-carboxyglutamic acid residues synthesis by insulin-like growth factor-I and vitamin K2 in human osteosarcoma cell line MG-63., Eur. J. Endocrinol.
    Lipps et al., 1996, Cathepsin B of Schistosoma mansoni. Purification and activation of the recombinant proenzyme secreted by Saccharomyces cerevisiae., J. Biol. Chem.

  • PharmGKB: coumarin

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Pitarque M et al., 2001, Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity., Biochem Biophys Res Commun
    Li L et al., 2006, New cytochrome P450 2D6*56 allele identified by genotype/phenotype analysis of cryopreserved human hepatocytes., Drug Metab Dispos
    Oscarson M et al., 1999, Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism., FEBS Lett

  • ChemblDrugs: chembl:CHEMBL6466

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21